Q2 2025 Management View CEO Jack A. Khattar stated that "Supernus continues to execute well against its growth plan and had a strong and very active second quarter." He highlighted the April launch of ...

ONAPGO demand is exceeding the Company's expectations, with more than 750 enrollment forms submitted by more than 300 prescribers through the end of the second quarter of 2025. Product Pipeline Update ...

The company launched ONAPGO, a subcutaneous apomorphine infusion device for advanced Parkinson’s disease, early in Q2. Initial physician response has been positive, with over 100 prescribers ...

In trial, Onapgo – formerly known as SPN-830 – significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment (0.58 hours).

Supernus should be a comfortable hold with a possibility for alpha if its Qelbree/ONAPGO growth combo can outperform. With a PE [FWD] of 13.74 and a market cap of $2.18 billion, it is reasonably ...

FDA Approves ONAPGO Apomorphine Hydrochloride For Parkinson's Disease Treatment February 04, 2025 — 11:27 am EST Written by RTTNews.com for RTTNews -> ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous ...

“With Onapgo, the continuous infusion of apomorphine directly stimulates postsynaptic dopamine receptors with no metabolic conversion needed,” said Stuart Isaacson, MD, Director of Parkinson ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

At 12 weeks from baseline, patients using Onapgo (compared with placebo) experienced a significantly reduced amount of daily OFF time (reduction of 2.6 versus 0.9 hours).

The FDA approval was based on a clinical trial involving 107 people. After 12 weeks, Onapgo reduced daily "off" time by 2.6 hours and increased "on" time by 2.8 hours, compared to 0.9 hours and 1. ...

Onapgo is supplied in single-dose cartridges containing 98mg/20mL of apomorphine HCl. It is administered as an SC infusion with the Onapgo pump.